ArticleCureus2025
Assessing Factors in Time to Diagnosis for Head-and-Neck Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives This study aimed to identify and evaluate factors influencing time to diagnosis (TTD) in head-and-neck (H&N) lymphoma, including fine-needle biopsy (FNA), and identify points of improvement in the management practice of H&N lymphoma. Methods This retrospective cohort study was conducted at University of Missouri, a tertiary care health system in Columbia, Missouri. Electronical medical records were reviewed to identify all patients who presented to otolaryngology and were subsequently diagnosed with lymphoma in the H&N region. Demographic and clinical factors influencing TTD, defined as time from initial clinical visit to final pathologic result, were evaluated using Cox proportional hazards multivariable regression modelling and visualized using Kaplan-Meier survival curves. Results Our study sample had 137 patients, most of whom presented with the primary symptom of neck mass/lymphadenopathy (81.0%). A personal history of lymphoma (HR 1.81 (1.03, 3.18); p = 0.04) and initial presenting symptoms of other than lymphadenopathy or neck mass (e.g., imaging findings, HR 2.12 (1.26, 3.59); p < 0.01) were factors associated with shorter TTD, whereas older age (HR 0.98 (0.97, 0.99) per year; p < 0.01) portends longer TTD. While FNA completed by ENT had a higher proportion of above median TTD (64.5% vs 40.0%; p < 0.01) on univariate analysis, this finding was not presenting after controlling for covariables (HR 0.93 (0.63, 1.39); p = 0.73). Conclusion We identified several factors associated with TTD in H&D lymphoma. FNA for lesions subsequently diagnosed as lymphoma does not clearly lengthen TTD, after controlling for confounders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.